Richard L. Lindstrom, MD, appointed founder, chairman of Surface Ophthalmics
Click Here to Manage Email Alerts
Key takeaways:
- Richard L. Lindstrom, MD, will lead Surface Ophthalmics as founder and chairman.
- Lindstrom will help advance Surface’s dry eye treatment portfolio.
Healio | OSN Chief Medical Editor Richard L. Lindstrom, MD, a leader in corneal, cataract, refractive and laser surgery, has been appointed as founder and chairman of Surface Ophthalmics, according to a press release.
“The management of dry eye syndrome (DES) remains a daily challenge for every eye care professional worldwide,” Lindstrom told Healio. “The global commercial opportunity is several billion dollars and growing. We doctors have learned there are several subcategories of DES that respond best to targeted treatments. Surface Ophthalmics is focused on treating DES associated with hyperosmolarity, inflammation, surface epitheliopathy with corneal staining and surgical transient ocular discomfort syndrome with proprietary and patented over-the-counter and prescription eye drops.”
In his new role, Lindstrom will help advance Surface’s portfolio of dry eye treatments, which includes Kera Sol tears, an over-the-counter solution for cell-compatible, short-term, fast-acting, temporary relief of burning and irritation caused by eye dryness, and Mycosol (Surf-101), a first-in-class prescription eye drop that delivers mycophenolate in a proprietary formulation.
Lindstrom will lead the company alongside Surface’s board of directors, including lead director Adrienne Graves, PhD, as well as Perry J. Sternberg, Shelley Thunen and J. Andy Corley.
Collapse
Click Here to Manage Email Alerts